PhRMA’s Post

In the path to find treatments for Alzheimer’s disease, we should look at previous setbacks not as failures but as learnings that have led us to where we are today. I spoke with Eli Lilly and Company's Anne White on how these learnings are bringing hope to patients and caregivers and how we can keep up investment in this space so we can #ENDALZ: https://lnkd.in/dPR9ZuCK 

The advent of new therapies from Biogen/Eisai (Leqembi) and Eli Lilly (donanemab) targeting the underlying causes of Alzheimer’s disease has marked a major advancement in treatment of the disease. Learn how these therapies work and how analysts view their revenue prospects in the coming years, according to Visible Alpha consensus. https://hubs.li/Q0216NTf0 #healthcare #visiblealphaconsensus #marketinsights #alzheimerstreatment

In July 2023, Leqembi® became the first disease-modifying treatment to receive traditional approval from the FDA. Making this new therapy available has required health systems to pivot and collaborate to ensure access and safety. On June 27, the webinar “A new era of treatment: Lessons in anti-amyloid care pathways” will review available treatments and therapies for Alzheimer's disease, key considerations for ensuring safe access to new therapies and nonpharmacologic strategies for caring for and treating Alzheimer's and related dementias. It’s presented in partnership with HANYS and New York Presbyterian/Columbia University. https://bit.ly/4bDVr6U

In July 2023, Leqembi® became the first disease-modifying treatment to receive traditional approval from the FDA. Making this new therapy available has required health systems to pivot and collaborate to ensure access and safety. On June 27, the webinar “A new era of treatment: Lessons in anti-amyloid care pathways” will review available treatments and therapies for Alzheimer's disease, key considerations for ensuring safe access to new therapies and nonpharmacologic strategies for caring for and treating Alzheimer's and related dementias. It’s presented in partnership with HANYS and New York Presbyterian/Columbia University. https://bit.ly/4bDVr6U

In July 2023, Leqembi® became the first disease-modifying treatment to receive traditional approval from the FDA. Making this new therapy available has required health systems to pivot and collaborate to ensure access and safety. On June 27, the webinar “A new era of treatment: Lessons in anti-amyloid care pathways” will review available treatments and therapies for Alzheimer's disease, key considerations for ensuring safe access to new therapies and nonpharmacologic strategies for caring for and treating Alzheimer's and related dementias. It’s presented in partnership with HANYS and New York Presbyterian/Columbia University. https://bit.ly/4bDVr6U

As Micheal J. Fox is recognized by Time Magazine on the 2024 TIME100 list, I want to re-share my interview with Cathy Molohan who lives with Parkinson's Disease. Cathy is passionate about getting patients involved in the design of clinical trial protocols, as well as advancing research in Parkinson's Disease. She shares her frustration with the lack of advancement in stopping the disease progression, considering Levodopa is still the treatment of choice more than 60 years after its first use in PD patients. The work that Cathy and others do to raise awareness about Parkinson's Disease is so important. We need more research, more clinical trials, and hopefully new treatments, to stop its progression. Listen to the interview: https://lnkd.in/eiUKPQ-Q #parkinson #parkinsonsdisease #pd #levodopa #deepbrainstimulation #patientadvocacy

We talk so often about costs in healthcare, but how often do we pause to ask: Whose costs? I'm looking forward to this The Innovation and Value Initiative (IVI) webinar to explore the full range of economic impacts that patients and their families experience. #healthequity #measurewhatmatters #livedexperience

Parkinson's disease can't be diagnosed through a simple blood test or scan. After a referral from a primary care doctor, it often takes visits to a neurologist or movement disorder specialist before receiving a clinical diagnosis. Tune in to hear healthcare providers and those living with the disease talk about the diagnostic process. We also explain how to build a Parkinson's care team - a group of healthcare providers that provide support after diagnosis.Listen now: https://lnkd.in/eFj2Xdhr #Parkinsons #ParkinsonsDisease #PD Altoida, Inc. , PD Avengers, Parkinson's Foundation, The Michael J. Fox Foundation for Parkinson's Research , Parkinson's Europe , World Parkinson Coalition , Davis Phinney Foundation , Brian Grant Foundation

Parkinson's disease can't be diagnosed through a simple blood test or scan. After a referral from a primary care doctor, it often takes visits to a neurologist or movement disorder specialist before receiving a clinical diagnosis. Tune in to hear healthcare providers and those living with the disease talk about the diagnostic process. We also explain how to build a Parkinson's care team - a group of healthcare providers that provide support after diagnosis.Listen now: https://lnkd.in/e4uFywxs #Parkinsons #ParkinsonsDisease #PD Altoida, Inc. , PD Avengers, Parkinson's Foundation, The Michael J. Fox Foundation for Parkinson's Research , Parkinson's Europe , World Parkinson Coalition , Davis Phinney Foundation , Brian Grant Foundation

Parkinson's disease can't be diagnosed through a simple blood test or scan. After a referral from a primary care doctor, it often takes visits to a neurologist or movement disorder specialist before receiving a clinical diagnosis. Tune in to hear healthcare providers and those living with the disease talk about the diagnostic process. We also explain how to build a Parkinson's care team - a group of healthcare providers that provide support after diagnosis.Listen now: https://lnkd.in/e4uFywxs #Parkinsons #ParkinsonsDisease #PD Altoida, Inc. , PD Avengers, Parkinson's Foundation, The Michael J. Fox Foundation for Parkinson's Research , Parkinson's Europe , World Parkinson Coalition , Davis Phinney Foundation , Brian Grant Foundation